News from the healthcare data industry
30-11-2021 The US Food and Drug Administration (FDA) has issued a draft guidance for drugmakers relating to the use of real-world evidence (RWE). In the guidance, titled Real-World Data: Assessing Registries...
By Stacy Cline Amin, Morrison & Foerster; former chief counsel of the FDA Health policy experts have talked excitedly about the potential for real-world evidence (RWE) to transform healthcare delivery...
DUBLIN, Ohio, Oct. 28, 2021 /PRNewswire/ — Cardinal Health (NYSE: CAH) announced today it has been awarded a $750,000 contract by the U.S. Food and Drug Administration (FDA) to implement an 18-month real world evidence (RWE)...
NEW YORK, NY, October 21, 2021 — Today, Aetion announces that it is expanding its relationship with the U.S. Food and Drug Administration (FDA) to use real-world evidence (RWE) to study...
October 1, 2021 Jill Wechsler, Pharm Exec’s Washington Correspondent Demand for more efficient and faster development of medical products is prompting regulatory authorities to incorporate additional sources of information into...
Download Guidance here: https://www.fda.gov/media/152503/download